- Home
- ALT vs MCS Comparison
ALT vs MCS Comparison
Compare ALT & MCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | MCS |
|---|---|---|
| Founded | 1997 | 1935 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.3M | 482.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALT | MCS |
|---|---|---|
| Price | $3.61 | $15.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $16.33 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 4.8M | 217.4K |
| Earning Date | 11-06-2025 | 10-31-2025 |
| Dividend Yield | N/A | ★ 2.05% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $20,000.00 | ★ $712,239,000.00 |
| Revenue This Year | N/A | $10.32 |
| Revenue Next Year | N/A | $5.27 |
| P/E Ratio | ★ N/A | $63.59 |
| Revenue Growth | N/A | ★ 6.27 |
| 52 Week Low | $2.90 | $12.85 |
| 52 Week High | $7.83 | $22.38 |
Technical Indicators
Market Signals| Indicator | ALT | MCS |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 52.67 |
| Support Level | $3.83 | $15.08 |
| Resistance Level | $5.37 | $15.92 |
| Average True Range (ATR) | 0.33 | 0.35 |
| MACD | -0.19 | -0.05 |
| Stochastic Oscillator | 0.82 | 38.52 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.